
Frontier Medicines is a precision medicine company that has pioneered a proprietary discovery and development platform to develop medicines against disease-causing proteins previously considered undruggable. They utilize groundbreaking scientific approaches in chemoproteomics, covalent drug discovery, and machine learning to create innovative therapies, particularly in oncology. Their lead program, FMC-376, targets KRASG12C mutations prevalent in various cancers. Frontier's collaboration with AbbVie aims to develop novel therapies against challenging protein targets, significantly broadening the therapeutic landscape.

Frontier Medicines is a precision medicine company that has pioneered a proprietary discovery and development platform to develop medicines against disease-causing proteins previously considered undruggable. They utilize groundbreaking scientific approaches in chemoproteomics, covalent drug discovery, and machine learning to create innovative therapies, particularly in oncology. Their lead program, FMC-376, targets KRASG12C mutations prevalent in various cancers. Frontier's collaboration with AbbVie aims to develop novel therapies against challenging protein targets, significantly broadening the therapeutic landscape.
Sector: Biotechnology Research — precision small-molecule therapeutics
Platform: Frontier™ platform: chemoproteomics + covalent discovery + machine learning
Lead programs: FMC-376 (KRASG12C, clinical) and FMC-220 (p53 Y220C, preclinical)
Founded: 2018
Known funding (total reported): USD 255,500,000
Offices: South San Francisco and Boston
Targeting previously undruggable, disease-causing proteins in oncology via covalent small-molecule approaches.
2018
Biotechnology Research
67000000 USD
88500000 USD
80000000 USD
Reported as oversubscribed; included strategic investor participation
“Backed by venture and crossover investors including Deerfield Management, RA Capital, Woodline Partners, MPM Capital, Droia Ventures, DCVC Bio, RA Capital Management, Galapagos, ArrowMark Partners and others”
| Company |
|---|
Frontier Medicines is seeking a highly motivated individual to fill the position of Principal Scientist, Computational Chemistry. The successful candidate will play a leading role in developing medicinal chemistry optimization strategies for key drug discovery programs. This individual will review experimental results, develop SAR hypotheses for activity, selectivity, and properties, and make design suggestions to improve the profiles of small molecule drug candidates.
As a covalent drug discovery–focused company, there is the opportunity for method development within this evolving field, in addition to applying the full range of ligand-based and structure-based design approaches and leveraging data from chemoproteomics, AI and quantum mechanics.
This role is key to Frontier Medicines’ success and an opportunity to work in a highly collaborative and energetic environment with short communication lines across functions and departments, and regular interactions with senior leaders. As the senior computational chemist, there is furthermore an opportunity to build out the computational team in the future
Requirements What will you be doing?
What are we looking for?
Benefits
At Frontier, we strive to build a diverse and equitable workplace. The salary range for this role is $175,000 - $231,000. Compensation for the role will depend on a number of factors, including candidates' qualifications, skills, competencies and experience. Frontier offers a competitive total rewards package which includes healthcare coverage, 401k and a broad range of other benefits. This compensation and benefits information is based on Frontier's knowledge as of the date of publication, and may be modified in the future.